INTRODUCTION

49
Orally administered antiretroviral drugs (ARVs) are now important for reducing viral loads in infected individuals and preventing the worldwide spread of HIV-1 infection (6, 14) . The vaginal 51 application of ARVs as 'microbicides' has also emerged as a key prevention strategy in protecting 52 women against infection (7, 23, 36, 41, 44) . It is now widely acknowledgeed that microbicides should 53 be based on ARVs similar to those used for treatment, for reasons of potency and practicality (13, 20, 54 21). The positive outcome of the CAPRISA trial of the reverse transcriptase inhibitor (RTI) tenofovir 55 formally validates the concept of ARV-based microbicides (17, 18) . 56 57 In addition to RTIs, other classes of ARVs are also worth evaluating as microbicides, in part to counter 58 the increased spread of RTI-resistant viruses resulting from expanded treatment programs with same 59 drug class (42). Using more than one ARV class in a co-formulated microbicide could also increase 60 both the potency and breadth of protection (15, 34) . Small molecule CCR5 inhibitors represent one 61 such class, exemplified by the licensed drug maraviroc (MVC), which binds the CCR5 co-receptor and 62 prevents cell entry of the most frequently transmitted HIV-1 strains (24, 29, 35) . Both MVC and 63 another CCR5 inhibitor, CMPD167, have already been shown to prevent vaginal transmission of 64 SHIV-162P3 to macaques when delivered vaginally in an aqueous gel formulation (46, 47) . allowing it to absorb (5 min), before removal and immediate transport to a laboratory for processing.
139
The sponges were re-weighed, to calculate the collected vaginal fluid weight. The sponge tips were 140 removed and placed into Spin-X tubes containing a 40 µm filter separating top and bottom chambers.
141
Extraction buffer (300 µL) containing 0.25 M NaCl, 0.2% sodium azide and protease inhibitors 142 (Calbiochem) were added to the top well and the tubes centrifuged (13,000 g, 15 min). The top 143 chambers were removed and the samples stored (-80ºC) prior to MVC or CMPD167 quantification.
144
Blood samples were treated with EDTA before plasma was separated by centrifugation (1000 g, 20 145 min) and stored (-80ºC) prior to analysis. Pinch biopsies were sampled as previously described (11). Table 1 ), which will predominate in the normal vaginal pH range for both humans (pH 4-5) (32, 190 39) and rhesus macaques (pH 6-7) (40), has a logP of -0.32 (i.e., hydrophilic). CMPD167 contains one but were much lower overall at 1,000-20,000 ng/g ( Figures 2B and 2E Residual drug content measurements showed that ~3-fold greater amounts of MVC were delivered to 250 macaques over 28 days compared to CMPD167 (Figure 3 ). The differential is quantitatively consistent 251 with the better release of MVC from the rings in vitro (Figures 1, 3) , and with the pharmacokinetic MVC was more water-soluble than CMPD167 (~1 and ~0.5 mg/mL, respectively; Table 1 ), which was 275 reflected by the in vitro release data ( Figure 1 ) and macaque vaginal fluid levels (Figure 2A and 2D Nonetheless, blood levels were generally very low, particularly in macaques not given DP. Chinese), the challenge stock and dose, and the use of antibiotics to eliminate vaginal flora (4, 5, 22).
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We are conducting studies to understand how best to challenge macaques that have vaginal rings n/a n/a n/a VF:BP 1.63 E6 n/a 1.06 E6 n/a 3.85 E5 n/a n/a n/a on November 12, 2017 by guest
